These dual-function nanoparticles improve selectivity of myeloid treatment via identification and reduction of tumor progression in a two-step process: initial accumulation in tumor microenvironments, followed by targeted delivery of a therapeutic payload.
Researchers in Dr. Richard Zare's lab have developed solid lipid nanoparticles (SLNPs) that provide sustained in vivo delivery of small interfering RNAs (siRNAs). siRNAs can silence genes responsible for disease, which makes them promising tools for gene therapy.
Richard Zare's lab at Stanford University has developed a ground-breaking drug release system in which injected medication can be controlled externally with excellent spatial, temporal, and dosage control.